S&P 500   3,358.63 (+0.69%)
DOW   27,733.73 (+1.02%)
QQQ   279.05 (+1.12%)
AAPL   116.33 (+1.96%)
MSFT   210.41 (+1.52%)
FB   262.89 (+0.42%)
GOOGL   1,475.66 (+0.66%)
AMZN   3,168.06 (+0.74%)
TSLA   428.81 (+2.32%)
NVDA   542.06 (+2.46%)
BABA   291.91 (+5.41%)
CGC   14.37 (-0.90%)
GE   6.23 (+1.80%)
MU   47.52 (-6.29%)
AMD   82.59 (+1.00%)
T   28.46 (+0.57%)
F   6.64 (+0.61%)
ACB   4.66 (-0.43%)
GILD   62.97 (+1.40%)
NFLX   501.02 (+1.53%)
DIS   124.37 (-0.82%)
BA   166.66 (+1.87%)
BAC   24.06 (+1.22%)
S&P 500   3,358.63 (+0.69%)
DOW   27,733.73 (+1.02%)
QQQ   279.05 (+1.12%)
AAPL   116.33 (+1.96%)
MSFT   210.41 (+1.52%)
FB   262.89 (+0.42%)
GOOGL   1,475.66 (+0.66%)
AMZN   3,168.06 (+0.74%)
TSLA   428.81 (+2.32%)
NVDA   542.06 (+2.46%)
BABA   291.91 (+5.41%)
CGC   14.37 (-0.90%)
GE   6.23 (+1.80%)
MU   47.52 (-6.29%)
AMD   82.59 (+1.00%)
T   28.46 (+0.57%)
F   6.64 (+0.61%)
ACB   4.66 (-0.43%)
GILD   62.97 (+1.40%)
NFLX   501.02 (+1.53%)
DIS   124.37 (-0.82%)
BA   166.66 (+1.87%)
BAC   24.06 (+1.22%)
S&P 500   3,358.63 (+0.69%)
DOW   27,733.73 (+1.02%)
QQQ   279.05 (+1.12%)
AAPL   116.33 (+1.96%)
MSFT   210.41 (+1.52%)
FB   262.89 (+0.42%)
GOOGL   1,475.66 (+0.66%)
AMZN   3,168.06 (+0.74%)
TSLA   428.81 (+2.32%)
NVDA   542.06 (+2.46%)
BABA   291.91 (+5.41%)
CGC   14.37 (-0.90%)
GE   6.23 (+1.80%)
MU   47.52 (-6.29%)
AMD   82.59 (+1.00%)
T   28.46 (+0.57%)
F   6.64 (+0.61%)
ACB   4.66 (-0.43%)
GILD   62.97 (+1.40%)
NFLX   501.02 (+1.53%)
DIS   124.37 (-0.82%)
BA   166.66 (+1.87%)
BAC   24.06 (+1.22%)
S&P 500   3,358.63 (+0.69%)
DOW   27,733.73 (+1.02%)
QQQ   279.05 (+1.12%)
AAPL   116.33 (+1.96%)
MSFT   210.41 (+1.52%)
FB   262.89 (+0.42%)
GOOGL   1,475.66 (+0.66%)
AMZN   3,168.06 (+0.74%)
TSLA   428.81 (+2.32%)
NVDA   542.06 (+2.46%)
BABA   291.91 (+5.41%)
CGC   14.37 (-0.90%)
GE   6.23 (+1.80%)
MU   47.52 (-6.29%)
AMD   82.59 (+1.00%)
T   28.46 (+0.57%)
F   6.64 (+0.61%)
ACB   4.66 (-0.43%)
GILD   62.97 (+1.40%)
NFLX   501.02 (+1.53%)
DIS   124.37 (-0.82%)
BA   166.66 (+1.87%)
BAC   24.06 (+1.22%)
Log in
NASDAQ:ONCS

OncoSec Medical Stock Forecast, Price & News

$3.37
0.00 (0.00 %)
(As of 09/30/2020 02:32 PM ET)
Add
Compare
Today's Range
$3.26
Now: $3.37
$3.45
50-Day Range
$3.27
MA: $3.78
$4.50
52-Week Range
$1.04
Now: $3.37
$5.40
Volume2,106 shs
Average Volume287,910 shs
Market Capitalization$77.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.42
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. The company is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in the Phase IIb clinical trials (PISCES/KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in the Phase II clinical trials (OMS-141/KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, it undertakes the phase II monotherapy biomarker study in patients with advanced or metastatic TNBC. Further, the company has completed Phase I neoadjuvant clinical trial of ImmunoPulse IL-12 in combination with an anti-PD-1 in surgically resectable melanoma. Additionally, it is developing new DNA-encoded therapeutic candidates and tumor indications. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the PISCES/KEYNOTE-695 and OMS-141/KEYNOTE-890 studies; a collaboration with the GOG Foundation, Inc. to conduct a registration-enabled study of tavokinogene telseplasmid in women with recurrent/persistent cervical cancer; and a collaborative research agreement with Duke University School of Medicine in HER2+ breast cancer. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.
Read More
OncoSec Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.87 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.28 per share

Profitability

Net Income$-30,280,000.00

Miscellaneous

Employees33
Market Cap$77.62 million
Next Earnings Date10/5/2020 (Estimated)
OptionableNot Optionable
$3.37
0.00 (0.00 %)
(As of 09/30/2020 02:32 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONCS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions

How has OncoSec Medical's stock been impacted by Coronavirus (COVID-19)?

OncoSec Medical's stock was trading at $1.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONCS stock has increased by 146.0% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of OncoSec Medical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for OncoSec Medical
.

When is OncoSec Medical's next earnings date?

OncoSec Medical is scheduled to release its next quarterly earnings announcement on Monday, October 5th 2020.
View our earnings forecast for OncoSec Medical
.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Inc (NASDAQ:ONCS) issued its quarterly earnings results on Monday, June, 15th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.01.
View OncoSec Medical's earnings history
.

When did OncoSec Medical's stock split? How did OncoSec Medical's stock split work?

Shares of OncoSec Medical reverse split before market open on Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ONCS?

4 Wall Street analysts have issued 1-year price targets for OncoSec Medical's stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate OncoSec Medical's stock price to reach $7.38 in the next year. This suggests a possible upside of 118.8% from the stock's current price.
View analysts' price targets for OncoSec Medical
.

Are investors shorting OncoSec Medical?

OncoSec Medical saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 219,400 shares, a drop of 32.3% from the August 15th total of 324,300 shares. Based on an average trading volume of 369,300 shares, the short-interest ratio is currently 0.6 days.
View OncoSec Medical's Short Interest
.

Who are some of OncoSec Medical's key competitors?

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

Who are OncoSec Medical's key executives?

OncoSec Medical's management team includes the following people:
  • Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
  • Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 55)
  • Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 39)
  • Ms. Sara M. Bonstein, CFO, COO & Company Sec. (Age 38)
  • Dr. Christopher G. Twitty Ph.D., Chief Scientific Officer

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How do I buy shares of OncoSec Medical?

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoSec Medical's stock price today?

One share of ONCS stock can currently be purchased for approximately $3.37.

How big of a company is OncoSec Medical?

OncoSec Medical has a market capitalization of $77.62 million. OncoSec Medical employs 33 workers across the globe.

What is OncoSec Medical's official website?

The official website for OncoSec Medical is www.oncosec.com.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.